Recordati (REC.MI)
Quick facts
| Ticker | REC.MI (Borsa Italiana) |
|---|
Marketed products
- Carbaglu · Gastroenterology · revenue 200
Carbaglu works by activating the enzyme carbamoyl phosphate synthetase 1, which helps regulate ammonia levels in the body. - Isturisa · Respiratory · revenue 200
Isturisa blocks the production of cortisol in the adrenal glands by inhibiting the cytochrome P450 11B2 enzyme. - Cystadane · Infectious Disease
- Cosmegen · Oncology
Dactinomycin binds DNA and inhibits RNA synthesis, demonstrating cytotoxic activity in cancer models. - Peganone · Neuroscience
- Valchlor · Oncology
Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death. - Signifor · Oncology
Signifor works by binding to somatostatin receptors on the surface of cells, mimicking the natural hormone somatostatin to reduce cortisol production.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Recordati
What is the ticker symbol for Recordati?
Recordati trades as REC.MI on the Borsa Italiana.
What are Recordati's marketed drugs?
Top marketed products include Carbaglu, Isturisa, Cystadane, Cosmegen, Peganone, Valchlor.
How many employees does Recordati have?
Recordati has approximately 4,700 employees.